From Eli Lilly to Karuna Therapeutics to current owner Bristol Myers Squibb, the newly approved schizophrenia drug had quite ...
Leerink Partners analyst David Risinger has maintained their neutral stance on BMY stock, giving a Hold rating on September 26. David Risinger ...
India Today on MSN1d
US FDA approves new schizophrenia drugThe US FDA has approved a new drug, Cobenfy, for treating schizophrenia in adults. This is a first new class for medication ...
The Food and Drug Administration has approved Cobenfy (xanomeline and trospium chloride), making it the first major ...
The U.S. Food and Drug Administration (FDA) has approved Cobenfy (xanomeline and trospium chloride) for the treatment of ...
On Thursday, the U.S. Food and Drug Administration (FDA) approved the drug Cobenfy which targets schizophrenia in a new way.
The FDA approved Cobenfy, a new drug for people with schizophrenia that comes with fewer side effects than other ...
The US Food and Drug Administration (FDA) recently approved a new medication treatmeant, called Cobenfy, which is a ...
The FDA approved a new drug for schizophrenia. Discrimination is stressing Chinese Americans and damaging their mental health.
Bristol Myers gains FDA approval for a new schizophrenia drug. HHS declares a health emergency in Georgia due to Hurricane ...
This summary of current health news includes FDA approvals for new drugs by Bristol Myers and GE HealthCare, public health ...
While momentous, the approval of Cobenfy could also draw attention to an age-old problem in American healthcare: Will insurance barriers keep patients from getting an effective medicine?
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback